This company has been acquired
ETTX Stock Overview
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Entasis Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$3.88 |
| 52 Week Low | US$1.40 |
| Beta | 1.33 |
| 1 Month Change | 0% |
| 3 Month Change | 18.38% |
| 1 Year Change | -14.79% |
| 3 Year Change | -65.77% |
| 5 Year Change | n/a |
| Change since IPO | -79.46% |
Recent News & Updates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Shareholder Returns
| ETTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | -2.7% |
| 1Y | -14.8% | -12.9% | 9.1% |
Return vs Industry: ETTX exceeded the US Biotechs industry which returned -20.2% over the past year.
Return vs Market: ETTX exceeded the US Market which returned -17.2% over the past year.
Price Volatility
| ETTX volatility | |
|---|---|
| ETTX Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ETTX has not had significant price volatility in the past 3 months.
Volatility Over Time: ETTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 51 | Manos Perros | www.entasistx.com |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections.
Entasis Therapeutics Holdings Inc. Fundamentals Summary
| ETTX fundamental statistics | |
|---|---|
| Market cap | US$104.80m |
| Earnings (TTM) | -US$51.70m |
| Revenue (TTM) | n/a |
Is ETTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.70m |
| Earnings | -US$51.70m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 90.2% |
How did ETTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/11 03:10 |
| End of Day Share Price | 2022/07/08 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Entasis Therapeutics Holdings Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Louise Chen | Cantor Fitzgerald & Co. |